The multifunctional characteristics of SDOs, demonstrating both ACE and DPP-IV inhibitory activities [20], offer a distinctive opportunity for the development of dual-action preventive and therapeutic agents, potentially improving homeostasis and leading to effective approaches to treatment for patients with concurrent hypertension and diabetes. This evidence concerns the gene FAP and hypertensive disorder.